Download PDF
Synlett 2007(2): 0327-0329  
DOI: 10.1055/s-2007-967992
LETTER
© Georg Thieme Verlag Stuttgart · New York

Multicomponent Synthesis of Highly Substituted 2-Pyridones

Ana G. Neoa, Rosa María Carrilloa, Susana Barrigaa, Edelmiro Mománb, Stefano Marcaccinic, Carlos F. Marcos*a
a Laboratorio de Química Orgánica y Bioorgánica, LOBO, Departamento de Química Orgánica, Facultad de Veterinaria, Universidad de Extremadura, 10071 Cáceres, Spain
b Centre for Synthesis & Chemical Biology, Department of Pharmaceutical & Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Ireland
c Dipartimento di Chimica Organica ‘Ugo Schiff’, Università di Firenze, 50019 Sesto Fiorentino FI, Italy
Fax: +34(927)257110; e-Mail: cfernan@unex.es;
Further Information

Publication History

Received 14 June 2006
Publication Date:
24 January 2007 (online)

    Permissions and Reprints All articles of this category

Abstract

A novel synthesis of polyfunctionalised pyridones, ­structurally related to cardiotonic agent milrinone is described. The procedure consists of an Ugi four-component reaction of 3-formylchromones, followed by a base-promoted ring-opening/ring-closing process. Variation of three of the four components in the Ugi ­reaction allows access to the final products with a combinatorial distribution of ­substituents.

Key words

cyclisations - drugs - heterocycles - multicomponent ­reactions - pyridines

    References and Notes

  • 1 Dorigo P. Gaion RM. Belluco P. Fraccarollo D. Maragno I. Bombieri G. Benetollo F. Mosti L. Orsini F. J. Med. Chem.  1993,  36:  2475 
    CrossrefGoogle Scholar
  • For recent examples, see:
  • 3a Chen YH. Zhang HJ. Nan FJ. J. Comb. Chem.  2004,  6:  684 
    Article in Thieme ConnectGoogle Scholar
  • 3b Hachiya L. Ogura K. Shimizu M. Synthesis  2004,  1349 ; and the references therein
    Article in Thieme ConnectGoogle Scholar
  • See, for example:
  • 4a Fossa P. Menozzi G. Dorigo P. Floreani M. Mosti L. Bioorg. Med. Chem.  2003,  11:  4749 
    CrossrefGoogle Scholar
  • 4b Altomare C. Cellamare S. Summo L. Fossa P. Mosti L. Carotti A. Bioorg. Med. Chem.  2000,  8:  909 
    CrossrefGoogle Scholar
  • 4c Dorigo P. Fraccarollo D. Gaion RM. Santostasi G. Borea PA. Floreani M. Mosti L. Maragno I. Gen. Pharmacol.  1997,  28:  781 
    CrossrefGoogle Scholar
  • 4d Mosti L. Schenone P. Iester M. Dorigo P. Gaion RM. Fraccarollo D. Eur. J. Med. Chem.  1993,  28:  853 
    CrossrefGoogle Scholar
  • 5 Bossio R. Marcos CF. Marcaccini S. Pepino R. Heterocycles  1997,  45:  1589 
    CrossrefGoogle Scholar
  • 6 Beck B. Picard A. Herdtweck E. Dömling A. Org. Lett.  2004,  6:  39 
    CrossrefGoogle Scholar
  • 7a Marcaccini S. Pepino R. Marcos CF. Polo C. Torroba T. J. Heterocycl. Chem.  2000,  37:  1501 
    Article in Thieme ConnectGoogle Scholar
  • 7b Bossio R. Marcos CF. Marcaccini S. Pepino R. Synthesis  1997,  1389 
    Article in Thieme ConnectGoogle Scholar
  • 8 Ryabukhin SV. Plaskon AS. Volochnyuk DM. Tolmachev AA. Synlett  2004,  2287 
    Article in Thieme ConnectGoogle Scholar
  • 9 Jeon YH. Heo YS. Kim CM. Hyun YL. Lee TG. Ro S. Cho JM. CMLS, Cell. Mol. Life Sci.  2005,  62:  1198 
    CrossrefGoogle Scholar
  • Enamines 9 were identified by 1H NMR and 13C NMR as the major products obtained in the reactions with 4-chloro-aniline, 3,5-dichloroaniline, 4-nitroaniline and 1-amino-naphthalene. For example 1H NMR data of (Z)-3-[(4-chlorophenylamino)methylene]-2,3-dihydro-2-methoxy-chromen-4-one (9; R1 = H, R2 = 4-ClC6H4), obtained from 4-chloroaniline and 3-formylchromone, was identical to the published data:
  • 14a Fitton AO. Frost JR. Suschitzky H. Tetrahedron Lett.  1975,  16:  2099 
    CrossrefGoogle Scholar
  • 14b Fitton AO. Frost JR. Houghton PG. Suschitzky H. J. Chem. Soc., Perkin Trans. 1  1979,  1691 
    CrossrefGoogle Scholar
  • 15 Cristau P. Vors JP. Zhu J. Tetrahedron  2003,  59:  7859 
    CrossrefGoogle Scholar
2

Information obtained from the Investigational Drugs Database (IDDB, www.iddb3.com).

10

Synthesis of the Ugi adducts ( 7): General Procedure for Method A: 3-Formylchromone (3; R1 = H) or 6-methyl-2-formylchromone (3; R1 = CH3, 5 mmol) was dissolved in MeOH (5 mL). Amine 4 (5 mmol) was added, and the mixture was stirred for 15 min at r.t. Isocyanide 5 (5 mmol) and cyanoacetic acid (6; 5 mmol) were successively added and the mixture was stirred for 24-48 h at r.t. An abundant precipitate was formed, which was filtered and successively washed with i-PrOH and i-Pr2O, yielding a product pure enough to be used in the following reaction. For analytical purposes it may be further purified by recrystallisation from EtOH.

11

Representative Data: 2-Cyano- N -[cyclohexyl-carbamoyl(4-oxo-4 H -chromen-3-yl)methyl]- N -phenyl-acetamide ( 7a): Yield: 67%; white solid; mp 217-218 °C. IR: 3336, 2931, 2360, 1650, 1543, 1466, 761 cm-1. 1H NMR (400 MHz, CDCl3): δ = 8.15 (d, J = 8.1 Hz, 1 H), 8.03 (s, 1 H), 7.64 (t, J = 7.1 Hz, 1 H), 7.03-7.60 (m, 7 H), 6.47 (d, J = 8.4 Hz, 1 H), 6.31 (s, 1 H), 3.76-3.83 (m, 1 H), 3.33 (d, J = 18.5 Hz, 1 H), 3.17 (d, J = 18.5 Hz, 1 H,), 1.13-2.02 (m, 10 H). 13C NMR (100 MHz, CDCl3): δ = 175.83 (C), 167.79 (C), 162.88 (C), 158.06 (CH), 155.75 (C), 138.34 (C), 134.03 (CH), 129.78 (CH), 129.51 (CH), 125.84 (CH), 125.57 (CH), 123.30 (C), 118.17 (CH), 117.93 (C), 113.81 (C), 55.84 (CH), 48.98 (CH), 32.66 (CH2), 26.51 (CH2), 25.39 (CH2), 24.72 (CH2). MS (EI): m/z (%) = 444 (<1) [M+ + 1], 318 (12), 250 (100), 172 (3), 130 (5), 77 (2). HRMS: m/z calcd for C26H25N3O4: 443.1849; found: 443.1845.

12

Cyclisation of the Ugi Adducts ( 7): General Procedure: A 0.5 M solution of KOH in EtOH (1 mL, 0.5 mmol) was added to a solution of the Ugi adduct (7, 0.5 mmol) in EtOH (1 mL). The mixture was stirred for 8 h at r.t. and the orange-yellow precipitate obtained was filtered and washed with i-Pr2O, yielding compound 8 in an essentially pure form.

13

Representative Data for Potassium 5-Cyano-2-cyclohexylcarbamoyl-6-oxo-1-phenyl-1,6-dihydro-2 H -pyridin-3-ylidene(2-hydroxyphenyl)methanolate ( 8a): Yield: 75%; orange solid; mp 275 °C (dec.). IR: 3439, 2928, 2194, 1679, 1607, 1554, 1520, 1240, 771 cm-1. 1H NMR (400 MHz, DMSO): δ = 10.66 (s, 1 H), 7.56 (d, J = 8.1 Hz, 1 H), 7.31 (t, J = 8.0 Hz, 2 H), 7.23 (t, J = 7.1 Hz, 2 H), 7.11-7.19 (m, 3 H), 7.06 (s, 1 H), 6.86 (s, 1 H), 6.84 (s, 1 H), 5.28 (s, 1 H), 3.47-3.55 (m, 1 H), 1.04-1.75 (m, 10 H). 13C NMR (100 MHz, DMSO): δ = 183.28 (C), 169.91 (C), 164.31 (C), 156.83 (C), 147.65 (CH), 143.47 (C), 130.64 (CH), 129.59 (CH), 128.30 (CH), 125.68 (CH), 125.24 (C), 124.91 (CH), 122.21 (C), 118.34 (CH), 116.33 (CH), 105.83 (C), 78.28 (C), 62.07 (CH), 47.03 (CH), 32.34 (CH2), 31.93 (CH2), 25.42 (CH2), 25.23 (CH2), 23.85 (CH2). MS (FAB): m/z (%) = 520 (100) [M+ + K], 482 (96) [M+ +1], 444 (18), 376 (29), 356 (19), 355 (72), 338 (62), 317 (29). HRMS (FAB): m/z calcd for C26H25KN3O4: 482.1482; found: 482.1487.

16

Synthesis of the Ugi Adducts; Method B: Equimolar amounts of the four components and NH4Cl were stirred in toluene for 48 h at r.t. The resulting precipitate was filtered and successively washed with i-PrOH and hexanes.